Distinct Properties of Telmisartan on Agonistic Activities for Peroxisome Proliferator-Activated Receptor γ among Clinically Used Angiotensin II Receptor Blockers: Drug-Target Interaction Analyses-Reference-Cited by-同舟云学术

Distinct Properties of Telmisartan on Agonistic Activities for Peroxisome Proliferator-Activated Receptor γ among Clinically Used Angiotensin II Receptor Blockers: Drug-Target Interaction Analyses

Published:2014-01-14 Issue:1 Volume:349 Page:10-20
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Kakuta Hirotoshi,Kurosaki Eiji,Niimi Tatsuya,Gato Katsuhiko,Kawasaki Yuko,Suwa Akira,Honbou Kazuya,Yamaguchi Tomohiko,Okumura Hiroyuki,Sanagi Masanao,Tomura Yuichi,Orita Masaya,Yonemoto Takako,Masuzaki Hiroaki

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference65 articles.

1. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes

2. Structural basis for telmisartan-mediated partial activation of PPAR gamma

3. Telmisartan Prevents Obesity and Increases the Expression of Uncoupling Protein 1 in Diet-Induced Obese Mice

4. Avdeef A (2012). Permeability-PAMPA, in Absorption and Drug Development: Solubility, Permeability, and Charge State, 2nd ed, pp 319–498, Wiley, New York.

5. Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating Activity

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Telmisartan ameliorates nephropathy and restores the hippo pathway in rats with metabolic syndrome;European Journal of Pharmacology;2024-06

2. Association between types of antihypertensive medication and the risk of atrial fibrillation: a nationwide population study;Frontiers in Cardiovascular Medicine;2024-05-09

3. Effects of telmisartan on metabolic syndrome components: a comprehensive review;Biomedicine & Pharmacotherapy;2024-02

4. Improve Bioequivalence predictions with PAMPA Dissolution using Etoricoxib and five other Drug Formulations;Research Journal of Pharmaceutical Dosage Forms and Technology;2023-11-09

5. Enhancing Bioequivalence Predictions with PAMPA Dissolution Using Formulations of Telmisartan;Research Journal of Pharmaceutical Dosage Forms and Technology;2023-05-18